Obesity and activated protein C resistance

Pathophysiology of Haemostasis and Thrombosis

Volumn 36, Issue 2, 2008, Pages 64-68

  Solá, Eva ^a   Vayá, Amparo ^b   Villa, Piedad ^b   España, Francisco ^b   Estellés, Amparo ^b   García, Katherinne ^a   Hernández Mijares, Antonio ^a  

^a HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Hypercoagulability; Obesity; Protein C resistance, activated

Indexed keywords

PROTHROMBIN;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ANTHROPOMETRY; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIET THERAPY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBID OBESITY; PHENOTYPE; PRIORITY JOURNAL; THROMBOSIS; WEIGHT REDUCTION;

ACTIVATED PROTEIN C RESISTANCE; ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; OBESITY, MORBID; PEPTIDE FRAGMENTS; PROTHROMBIN; WEIGHT LOSS; YOUNG ADULT;

EID: 58549105949     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000173723     Document Type: Article

References (25)

1. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Rosner B, Monson RR, Speizer FE, Hennekens CH: A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1990;322:882-889.
2. Hamad GG, Choban PS: Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study. Obes Surg 2005;15:1368-1374.
3. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, Wu KK: Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993;70:380-385.
4. Avellone G, Di Garbo V, Cordova R, Cucinella G, De Simone R, Raneli G, Bompiani G: Evaluation of cardiovascular risk factors in overweight and obese subjects. Int Angiol 1994;13:25-29.
5. De Pergola G, De Mitrio V, Giorgino F, Sciaraffia M, Minenna A, Di Bari L, Pannacciulli N, Giorgino R: Increase in both pro-thrombotic and anti-thrombotic factors in obese premenopausal women: relationship with body fat distribution. Int J Obes Relat Metab Disord 1997;21:527-535.
6. Rodeghiero F, Tosetto A: The epidemiology of inherited thrombophilia: the VITA Project. Vicenza Thrombophilia and Atherosclerosis Project. Thromb Haemost 1997;78:636-640.
7. Tosetto A, Missiaglia E, Gatto E, Rodeghiero F: The VITA project: phenotypic resistance to activated protein C and FV Leiden mutation in the general population. Vicenza Thrombophilia and Atherosclerosis. Thromb Haemost 1997;78:859-863.
8. Lowe GD, Rumley A, Woodward M, Reid E, Rumley J: Activated protein C resistance and the FV:R506Q mutation in a random population sample - associations with cardiovascular risk factors and coagulation variables. Thromb Haemost 1999;81:918-924.
9. van der Bom JG, Bots ML, Haverkate F, Slagboom PE, Meijer P, de Jong PT, Hofman A, Grobbee DE, Kluft C: Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med 1996;125:265-269.
10. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2005;28:S37-S42.
11. Dahlbäck B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-1008.
12. Bertina RM: Laboratory diagnosis of resistance to activated protein C (APC-resistance). Thromb Haemost 1997;78:478-482.
13. Gandrille S, Alhenc-Gelas M, Aiach M: A rapid screening method for the factor V Arg506->Gln mutation. Blood Coagul Fibrinolysis 1995;6: 245-248.
14. Clark P, Walker ID: The phenomenon known as acquired activated protein C resistance. Br J Haematol 2001;115:767-773.
15. Dahlbäck B: Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis. Thromb Haemost 1997;78:483-488.
16. Clark P, Brennand J, Conkie JA, McCall F, Greer IA, Walker ID: Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998;79:1166-1170.
17. Laffan MA, Manning R: The influence of factor VIII on measurement of activated protein C resistance. Blood Coagul Fibrinolysis 1996;7:761-765.
18. Rosing J, Tans G, Nicolaes GA, Thomassen MC, van Oerle R, van der Ploeg PM, Heijnen P, Hamulyak K, Hemker HC: Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997;97:233-238.
19. Bokarewa MI, Blomback M, Egberg N, Rosen S: A new variant of interaction between phospholipid antibodies and the protein C system. Blood Coagul Fibrinolysis 1994;5:37-41.
20. Mathonnet F, de Mazancourt P, Denninger MH, Morot M, Benattar N, Giudicelli Y: Role of factor VIII on activated protein C resistance ratio in inflammatory diseases. Br J Haematol 1996;95:423-425.
21. Griffin JH, Fernandez JA, Deguchi H: Plasma lipoproteins, hemostasis and thrombosis. Thromb Haemost 2001;86:386-394.
22. Griffin JH, Kojima K, Banka CL, Curtiss LK, Fernández JA: High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 1999;103:219-227.
23. Deguchi H, Fernandez JA, Pabinger I, Heit JA, Griffin JH: Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway. Blood 2001;97:1907-1914.
24. Deguchi H, Bouma BN, Middeldorp S, Lee YM, Griffin JH: Decreased plasma sensitivity to activated protein C by oral contraceptives is associated with decreases in plasma glucosylceramide. J Thromb Haemost 2005;3:935-938.
25. Bowles LK, Cooper JA, Howarth DJ, Miller GJ, MacCallum PK: Associations of haemostatic variables with body mass index: a community-based study. Blood Coagul Fibrinolysis 2003;14:569-573.